Sweeney, C., Proudfoot, J. A., Kaur, S., Thompson, D., Stockler, M. R., Guilhaus, M., Thomas, H., Subhash, V., Oakes, S. R., Grist, E., Hamid, A., Yip, S., Azad, A., Horvath, L., Kench, J. G., Davicioni, E., Attard, G., Davis, I. D. (2026). Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5001